Page 5 - Graybug Vision News Today

A robust pipeline of potential new treatments currently in Phases II and III is expected to drive the Diabetic Retinopathy Market ahead. LAS VEGAS, May 12, 2021 /PRNewswire/ -- DelveInsight's

Diabetic Macular Edema Market: Revenues Estimated to Climb Modestly at a CAGR of 3.2% During the Study Period 2018-2030 in the 7MM, Foresees DelveInsight LAS VEGAS, May 10, 2021 /PRNewswire/ -- DelveInsights Diabetic Macular Edema (DME) Market report offers detailed information on current treatment practices, emerging drugs, Diabetic Macular Edema market share of the individual therapies, current and forecasted Diabetic Macular Edema market size from 2018 to 2030 segmented into 7MM (the USA, E...

Share this article LAS VEGAS, March 17, 2021 /PRNewswire/ -- DelveInsights " Wet Age-Related Macular Degeneration (Wet AMD) Market" report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the Wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment...

    Tuesday morning, 4 companies set new 52-week lows. Things to Consider: DoorDash (NYSE:DASH) was the largest firm by market cap to set a new ...

Share this article —CAMMARATA HONORED BY HEALTHCARE TECHNOLOGY REPORT— LAVAL, QC, March 2, 2021 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ: NEPT) (TSX: NEPT) President and CEO Michael Cammarata has been named one of the Top 25 Biotech CEOs of 2021 by The Healthcare Technology Report. Mr. Cammarata has led Neptune Wellness Solutions Inc., a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and p...

The Fifth Annual Retina Fellow Summit This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 2.00 CME Activity Expiration Date: 12/31/2021 Activity Overview This activity features highlights captured from the Fifth Annual Retina Fellow Summit held in November 2020. The Summit included an expert faculty panel and an audience of retina fellows engaging in discussions on current clinical data, clinical cases, and practice transiti...

88 Biggest Movers From Yesterday Benzinga 12/24/2020 Gainers Ocugen, Inc. (NASDAQ: OCGN) shares climbed 222.9% to close at $2.60 on Wednesday after the company announced it will convene its Meeting of Stockholders on Dec. 23 to modify a proposal, decreasing the proposed aggregate number of shares of common stock that the Company would be authorized to issue. Ocugen shares jumped around 174% on Tuesday after the company and Bharat Biotech announced plans to co-develop a whole-virion inactivate...

Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast Report 2017-2030 - ResearchAndMarkets.com ResearchAndMarkets.coms offering. This Retinal Vein Occlusion - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the RVO, historical and forecasted epidemiology as well as the RVO market trends in the United States, EU5(Germany, France, Italy, Spain, and the United Kingdom) and Japan. The RVO market report provides current treatm...

The Retinal Vein Occlusion Market to Grow with a CAGR of 6.39% for the Study Period 2017-30 LAS VEGAS, Dec. 23, 2020 /PRNewswire/ -- DelveInsights Retinal vein occlusion (RVO) market report delivers an in-depth understanding of the RVO, historical and forecasted epidemiology as well as the Retinal vein occlusion market trends, current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Retinal vein occlusion market size, unmet needs, dri...

Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029 ResearchAndMarkets.coms offering. Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF). The most frequently used anti-VEGF drugs are Roche/Genentechs humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regenerons fu...